These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32237644)

  • 1. [Are the two formulas of Levothyrox bioequivalent?].
    Coste J; Bertagna X; Zureik M; Nicolas P; Ramez P; Hill C; Schlumberger M
    Rev Prat; 2019 Oct; 69(8):831-837. PubMed ID: 32237644
    [No Abstract]   [Full Text] [Related]  

  • 2. [Both formulas of Levothyrox are not bioequivalent].
    Hill C; Schlumberger M
    Rev Prat; 2019 Jun; 69(6):599-601. PubMed ID: 31626414
    [No Abstract]   [Full Text] [Related]  

  • 3. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox
    Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD
    Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Levothyrox crisis].
    Bertagna X; Bouchard P; Grimaldi A; Wemeau JL; Young J; Rodien P; Reynaud R; Noël C; Bapt G
    Rev Prat; 2019 Sep; 69(7):721-728. PubMed ID: 32233310
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance database.
    Khouri C; Revol B; Lepelley M; Mallaret M; Cracowski JL
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1427-1428. PubMed ID: 30379373
    [No Abstract]   [Full Text] [Related]  

  • 6. The French Levothyrox
    Mouly S; Roustit M; Bagheri H; Perault-Pochat MC; Molimard M; Bordet R
    Therapie; 2019 Jun; 74(3):431-435. PubMed ID: 30737052
    [No Abstract]   [Full Text] [Related]  

  • 7. [Lévothyrox
    Wémeau JL; Ladsous M
    Presse Med; 2017 Oct; 46(10):887-889. PubMed ID: 29108724
    [No Abstract]   [Full Text] [Related]  

  • 8. The equivalency of two L-thyroxine preparations.
    Hennessey JV; Burman KD; Wartofsky L
    Ann Intern Med; 1985 Jun; 102(6):770-3. PubMed ID: 3922270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.
    Gottwald-Hostalek U; Uhl W; Wolna P; Kahaly GJ
    Curr Med Res Opin; 2017 Feb; 33(2):169-174. PubMed ID: 27718637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles.
    Vaisman M; Spina LD; Eksterman LF; dos Santos MJ; Lima JS; Volpato NM; da Silva RL; de Brito AP; Noël F
    Arzneimittelforschung; 2001; 51(3):246-52. PubMed ID: 11304941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levothyroxine sodium tablets: chemical equivalence and bioequivalence.
    Curry SH; Gums JG; Williams LL; Curry RW; Wolfson BB
    Drug Intell Clin Pharm; 1988; 22(7-8):589-91. PubMed ID: 3046889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Levothyrox : time of reason].
    Bertagna X; Bouchard P; Grimaldi A; Wémeau JL; Young J
    Rev Prat; 2018 Feb; 68(2):123-125. PubMed ID: 30801135
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
    Dong BJ; Hauck WW; Gambertoglio JG; Gee L; White JR; Bubp JL; Greenspan FS
    JAMA; 1997 Apr; 277(15):1205-13. PubMed ID: 9103344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral thyroxine.
    Boehler J
    Ann Intern Med; 1984 Oct; 101(4):572-3. PubMed ID: 6476653
    [No Abstract]   [Full Text] [Related]  

  • 16. Thyroxine bioequivalency.
    Ann Intern Med; 1985 Oct; 103(4):646-7. PubMed ID: 4037577
    [No Abstract]   [Full Text] [Related]  

  • 17. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
    Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonequality of brand name thyroxine preparations.
    Jacobson JM; Ramos-Gabatin A; Young RL; Watkins SC; Brown ML
    JAMA; 1980 Feb 22-29; 243(8):733. PubMed ID: 7351814
    [No Abstract]   [Full Text] [Related]  

  • 19. The Regulation of Biosimilars in Latin America.
    Garcia R; Araujo DV
    Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
    Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
    Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.